A Phase 1 interventional study of Ertugliflozin and Placebo to Ertugliflozin in Healthy Volunteer, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-05-29.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Ertugliflozin (PF-04971729, MK-8835) is under development for the treatment of Type 2 Diabetes. The primary purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, of multiple oral doses of ertugliflozin.
To evaluate the safety and tolerability, pharmacokinetics (PK), and pharmacodynamics, of multiple oral doses of ertugliflozin.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive.
(BMI) of 26.5 to 35.5 kg/m2; and a total body weight >50 kg (110 lbs).
Exclusion Criteria:
Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
Evidence of glycosuria, as defined by a positive urine dipstick test; Fasting (at least 10 hours) serum triglyceride >300 mg/dL; Fasting (at least 10 hours) LDL-cholesterol >190 mg/dL; Fasting (at least 10 hours) serum 25-OH Vitamin D concentration \<20 ng/mL
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ertugliflozin 1 mg, oral, once daily for 14 days
Drug: Ertugliflozin
Ertugliflozin up to 5 mg, oral, once daily for 14 days
Drug: Ertugliflozin
Ertugliflozin up to 25 mg, oral, once daily for 14 days
Drug: Ertugliflozin
Ertugliflozin up to 100 mg, once daily for 14 days
Drug: Ertugliflozin
Placebo to Ertugliflozin once daily for 14 days
Drug: Placebo to Ertugliflozin
Ertugliflozin oral dosing 1 mg, 5 mg, 25 mg, or 100 mg solutions/suspensions administered once daily for 14 days immediately after breakfast
Also known as: PF-04971729, MK-8835
Placebo oral dosing solutions/suspensions administered once daily for 14 days immediately after breakfast
Number of Participants Experiencing an Adverse Event (AE)
Time frame: Up to 28 days postdose (Up to 42 days)
Number of Participants Discontinuing Study Drug Due to an AE
Time frame: Up to 14 days
Area under the plasma concentration-time curve (AUC) over the dosing interval tau (AUCtau) for ertugliflozin
Time frame: Up to 17 days
Maximum plasma concentration (Cmax) of ertugliflozin
Time frame: Up to 17 days
Time taken to reach the maximum observed plasma concentration (Tmax) of ertugliflozin
Time frame: Up to 17 days
Ertugliflozin half life (t1/2)
Time frame: Up to 17 Days
Apparent clearance (CL/F) after a single dose of ertugliflozin
Time frame: Up to 17 days
Apparent volume of distribution (Vz/F)
Time frame: Up to 17 days
Observed Accumulation Ratio of Area Under the Curve for the dosing interval of ertugliflozin (Rac[obs])
Time frame: Up to 17 days
Change from baseline in 24-hour weighted mean glucose
Time frame: Baseline and Day 14
Change from baseline in 24-hour urinary glucose excretion
Time frame: Baseline and Day 14
Change from baseline in 24-hour plasma C-peptide
Time frame: Baseline and Day 14
Inhibition of glucose reabsorption
Time frame: Baseline and Day 14
Change from baseline in body weight
Time frame: Baseline and Day 14
Area under the plasma concentration-time curve over 8 hours (AUC[0-8]) for serum intact parathyroid hormone
Time frame: Up to 17 days
Area under the plasma concentration-time curve over 24 hours (AUC[0-24]) for serum intact parathyroid hormone
Time frame: Up to 17 days
Trough concentration of serum intact parathyroid hormone (Ctrough)
Time frame: Up to 17 days
No study locations are listed for this record.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Dec 2009 to primary completion in Mar 2010, 3 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ertugliflozin